These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 35715573)

  • 21. Tolvaptan for Treatment of Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) in a Child with Corpus Callosum Agenesis.
    Meena AK; Nanda PM; Sharma R; Chakrabarty B; Gulati S
    Indian J Pediatr; 2024 Feb; 91(2):188-190. PubMed ID: 36757652
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vasopressin receptor antagonist in the treatment of the syndrome of inappropriate antidiuretic hormone in general hospital practice.
    Rajendran R; Grossman AB; Kar P
    Endocr J; 2012; 59(10):903-9. PubMed ID: 22785335
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relapsing Syndrome of Inappropriate Antidiuretic Hormone Production Responding to Tolvaptan Treatment in a Patient With a Micronodular Formation of the Posterior Pituitary Gland.
    Reinke LM; Seoudy AK; Gärtner F; Rohmann N; Schulte DM; Schreiber S; Jansen O; Laudes M
    Exp Clin Endocrinol Diabetes; 2023 Sep; 131(9):472-475. PubMed ID: 37364592
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tolvaptan for SIADH in Myelodysplastic Syndrome with Blast Crisis.
    Mali P; Muduganti SR; Mujibur R; Murali N
    WMJ; 2015 Apr; 114(2):66-8. PubMed ID: 26756059
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of tolvaptan treatment between patients with the SIADH and congestive heart failure: a single-center experience.
    Park GH; Lee CM; Song JW; Jung MC; Kim JK; Song YR; Kim HJ; Kim SG
    Korean J Intern Med; 2018 May; 33(3):561-567. PubMed ID: 28286940
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low-dose tolvaptan PK/PD: comparison of patients with hyponatremia due to syndrome of inappropriate antidiuretic hormone secretion to healthy adults.
    Shoaf SE; Bricmont P; Dandurand A
    Eur J Clin Pharmacol; 2017 Nov; 73(11):1399-1408. PubMed ID: 28803333
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Open-label, multicenter, dose-titration study to determine the efficacy and safety of tolvaptan in Japanese patients with hyponatremia secondary to syndrome of inappropriate secretion of antidiuretic hormone.
    Arima H; Goto K; Motozawa T; Mouri M; Watanabe R; Hirano T; Ishikawa SE
    Endocr J; 2021 Jan; 68(1):17-29. PubMed ID: 32863282
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improving care and outcomes of inpatients with syndrome of inappropriate antidiuresis (SIAD): a prospective intervention study of intensive endocrine input vs. routine care.
    Tzoulis P; Carr H; Bagkeris E; Bouloux PM
    Endocrine; 2017 Feb; 55(2):539-546. PubMed ID: 27837439
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An economic analysis of tolvaptan compared with fluid restriction among hospitalized patients with hyponatremia.
    Ramamohan V; Mladsi D; Ronquest N; Kamat S; Boklage S
    Hosp Pract (1995); 2017 Aug; 45(3):111-117. PubMed ID: 28449624
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intravenous conivaptan for the treatment of hyponatraemia caused by the syndrome of inappropriate secretion of antidiuretic hormone in hospitalized patients: a single-centre experience.
    Velez JC; Dopson SJ; Sanders DS; Delay TA; Arthur JM
    Nephrol Dial Transplant; 2010 May; 25(5):1524-31. PubMed ID: 20064953
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A rapid and efficient way to manage hyponatremia in patients with SIADH and small cell lung cancer: treatment with tolvaptan.
    Petereit C; Zaba O; Teber I; Lüders H; Grohé C
    BMC Pulm Med; 2013 Aug; 13():55. PubMed ID: 23987478
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum and urine responses to the aquaretic agent tolvaptan in hospitalized hyponatremic patients.
    Vaghasiya RP; DeVita MV; Michelis MF
    Int Urol Nephrol; 2012 Jun; 44(3):865-71. PubMed ID: 21607553
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of the syndrome of inappropriate secretion of antidiuretic hormone with urea in critically ill patients.
    Coussement J; Danguy C; Zouaoui-Boudjeltia K; Defrance P; Bankir L; Biston P; Piagnerelli M
    Am J Nephrol; 2012; 35(3):265-70. PubMed ID: 22378162
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Diagnostics and new treatment methods of syndrome of inappropriate antidiuretic hormone secretion (SIADH)].
    Trolle C; Rittig S; Frøkjær J; Jørgensen JO
    Ugeskr Laeger; 2012 Apr; 174(15):1019-22. PubMed ID: 22487409
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prompt efficacy of tolvaptan in treating hyponatremia of syndrome of inappropriate secretion of antidiuretic hormone (SIADH) closely associated with rupture of a gastric artery aneurysm.
    Yamashita T; Yoshida M; Yamada H; Asano T; Aoki A; Ikoma A; Kusaka I; Kakei M; Ishikawa SE
    Intern Med; 2014; 53(8):845-9. PubMed ID: 24739604
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The use of tolvaptan in a case of severe hyponatriemia in SIADH during meningitis].
    Rollino C; Balbiano R; Caramello P; Roccatello D
    G Ital Nefrol; 2013; 30(6):. PubMed ID: 24402662
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of long-term tolvaptan treatment in a patient with SCLC and SIADH.
    Bordi P; Tiseo M; Buti S; Regolisti G; Ardizzoni A
    Tumori; 2015 Apr; 101(2):e51-3. PubMed ID: 25702667
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of costs associated with tolvaptan-mediated hospital length of stay reduction among US patients with the syndrome of inappropriate antidiuretic hormone secretion, based on SALT-1 and SALT-2 trials.
    Dasta JF; Chiong JR; Christian R; Lin J
    Hosp Pract (1995); 2012 Feb; 40(1):7-14. PubMed ID: 22406878
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [A case of venlafaxine-induced syndrome of inappropriate ADH secretion (SIADH) - treatment with tolvaptan].
    Meyer I; Frank D; Janssens U
    Dtsch Med Wochenschr; 2012 May; 137(21):1096-9. PubMed ID: 22588654
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [A case of SIADH due to pancreatic cancer was improved by tolvaptan].
    Matsuyama S; Ueo T; Ozawa T; Matsumoto A; Minami R; Kimura Y; Takeda Y; Okano A; Kusumi F; Ohana M
    Nihon Shokakibyo Gakkai Zasshi; 2022; 119(2):172-178. PubMed ID: 35153267
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.